PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Recruiting now · Phase 2

Conditions studied: HER2 Insertion Mutation Positive Advanced NSCLC

In brief

The purpose of this study is to assess the safety and effectiveness of PD-1 Combined With Pyrotinib for First-line chemotherapy failed HER2 Insertion Mutation Positive Advanced Non-small Cell Lung Cancer

Key facts

Study ID

NCT04144569

Run by

Yongchang Zhang

People needed

30

Starts

2019-01-30

Expected to finish

2024-12-31

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced non-small cell lung cancer confirmed by histology or cytology
• HER2 insertion mutation-positive
• Failure with first-line standard chemotherapy
• with measurable lesions.

You may not qualify if…

• no measurable tumor lesions
• Patients received PD-1 or Pyrotinib before

Where it is running

• Hunan Provincal Tumor Hospital — Changsha, Hunan, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.